ライフサイエンスコーパス: asthenia

1 effort, and was associated with anorexia and asthenia.

2 o known as hereditary equine regional dermal asthenia.

3 common toxicities included rash, nausea, and asthenia.

4 oot syndrome, diarrhea, nausea/vomiting, and asthenia.

5 in the understanding of cancer cachexia and asthenia.

6 d therapy to manage both cancer cachexia and asthenia.

7 a, vomiting, pneumonia, dyspnea, anemia, and asthenia.

8 s of this docetaxel schedule are fatigue and asthenia.

9 events in more than 10% of all patients were asthenia (11 [18%] of 60 in the 12-week group; 19 [32%]

10 peripheral sensory neuropathy (14%), fatigue/asthenia (13%), myalgia (8%), and stomatitis/mucositis (

11 acebo), hypertension (34 [12%] vs ten [4%]), asthenia (14 [5%] vs five [2%]), malignant neoplasm prog

12 ere facial oedema (16 [64%] of 25 patients), asthenia (14 [56%]), and pruritus (14 [56%]).

13 geusia (269 [54%]), weight loss (162 [33%]), asthenia (141 [28%]), decreased appetite (126 [25%]), ag

14 ment-emergent adverse events were fatigue or asthenia (15 [12%] of 124 patients), hot flush (six [5%]

15 tening toxicity was experienced by 34%, with asthenia (15%) and neuropsychiatric difficulties (7%) be

16 The most common adverse events were asthenia (16 [39%] patients), headache (11 [27%] patient

17 vs 49 [16%]), fatigue (23 [7%] vs 18 [6%]), asthenia (16 [5%] vs 8 [3%]), bone pain (16 [5%] vs 5 [2

18 [14%] of 189 patients), diarrhoea (17 [9%]), asthenia (16 [8%]), weight decrease (16 [8%]), and PPE (

19 up were anorexia (31 [13%] of 240 patients), asthenia (20 [8%]), coughing (16 [7%]), abnormal behavio

20 ncluded neutropenic fever (24% of patients), asthenia (22%), infection (13%), stomatitis (9%), neuros

21 r 4 adverse events were neutropenia (39.0%), asthenia (22.0%), abdominal pain (22.0%), and thrombocyt

22 dverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%

23 r severe (grades 3 and 4) toxic effects were asthenia (25%), nausea (11%), fever (8%), vomiting (8%),

24 five [1%]), dyspnoea (22 [4%] vs nine [2%]), asthenia (27 [5%] vs 17 [3%]), and pulmonary embolism (3

25 ocytopenia (85.1%), neutropenia (63.8%), and asthenia (29.8%) in the escalation phase, and thrombocyt

26 hypertriglyceridemia (84%), dry skin (34%), asthenia (30%), and headache (27%).

27 ted adverse events of any grade were fatigue/asthenia (31.8%), infusion-related reaction (20.5%), and

28 dache (58 patients, 23% [95% CI 18-29]), and asthenia (35 patients, 14% [95% CI 10-19]).

29 bo group), fatigue (62 [8%] vs 42 [6%]), and asthenia (40 [5%] vs 23 [3%]); grade 3-4 pleural effusio

30 rade 1/2 adverse events were diarrhea (55%), asthenia (44%), and acne-like follicular rash (46%).

31 5%), anemia (8%), thrombocytopenia (7%), and asthenia (5%).

32 e maculopapular rash (76%), mucositis (70%), asthenia (50%), and nausea (43%).

33 rse events included hyperphosphatemia (65%), asthenia (55%), dry mouth (45%), nail toxicity (35%), co

34 f 98 patients), abnormal behaviour (6 [6%]), asthenia (6 [6%]), and pruritus (5 [5%]).

35 ents at the MTD were thrombocytopenia (90%), asthenia (67%), and nausea and neutropenia (51% each).

36 tomatitis (12.6%/1.8%), mucositis (9.0%/0%), asthenia (7.2%/0%), and hypertension (4.5%/0%).

37 (27 [66%] of 41]), diarrhoea (19 [46%]), and asthenia (8 [20%]).

38 elated grade 3/4 AEs were fatigue (9% v 1%), asthenia (8% v 2%), and hand-foot syndrome (7% v 0%).

39 uding headache, new injection site reaction, asthenia, abdominal pain, Crohn's disease-related anemia

40 Grade III to IV asthenia and fatigue were observed in 6% of patients.

41 The most frequent adverse events were asthenia and headache, pruritus, and fatigue.

42 dies, we also observed a higher incidence of asthenia and serious vascular thrombotic events than exp

43 an acne-like rash (88.6%), dry skin (34.3%), asthenia and skin disorders (31.4%), mucositis/stomatiti

44 reported adverse experiences were headache, asthenia, and constipation.

45 he most common adverse events were headache, asthenia, and gastrointestinal symptoms.

46 ommon adverse events were fatigue, insomnia, asthenia, and headache.

47 patients with grade 3 or 4 thrombocytopenia, asthenia, and liver toxicity was significantly higher in

48 adverse events, such as rhinitis, headache, asthenia, and peripheral edema, were reversible on drug

49 nal (diarrhea, nausea, stomatitis) toxicity, asthenia, and rash.

50 common toxicities included diarrhea, nausea, asthenia, and rash.

51 cycle included leukopenia, hypophosphatemia, asthenia, anemia, and hypertriglyceridemia for all patie

52 Common adverse events were asthenia, anorexia, pain, and somnolence.

53 Fatigue and asthenia are the DLTs; other nonhematologic toxicities,

54 curred in three patients (6.8%) and included asthenia, AST elevation, creatine phosphokinase elevatio

55 r not) in the anamorelin group were fatigue, asthenia, atrial fibrillation, and dyspnoea (two [5%] ea

56 itial infusion were mainly grade I/II fever, asthenia, chills, nausea, rash, and urticaria.

57 Cachexia and asthenia commonly coexist, but they can occur independen

58 rated and were associated with dose-limiting asthenia, diarrhea, and AST/ALT elevation.

59 y than nonpregnant women to report anorexia, asthenia, diarrhea, fever, myalgias/arthralgias, nausea,

60 9 patients in the placebo group), fatigue or asthenia (eight [4%] vs two [2%]), and neutropenia (ten

61 ommon of which were fatigue (four [2%]), and asthenia, elevated lipase, hypophosphataemia, and pneumo

62 The dose-limiting toxicity was asthenia, establishing the maximum tolerated dose of 27

63 of grade 3/4 neutropenia, thrombocytopenia, asthenia, fatigue, diarrhea, and hand-foot syndrome.

64 grade; 18% with grade 3), and a composite of asthenia, fatigue, malaise, or lethargy (56% with any gr

65 Therapy was generally well tolerated, but asthenia, fatigue, vertigo, dizziness, sense of imbalanc

66 er, including rash/dermatitis, diarrhea, and asthenia/fatigue were more frequent in the sunitinib plu

67 Vomiting, nausea, asthenia/fatigue, and anorexia were common but not sever

68 red by a number of adverse effects including asthenia/fatigue.

69 completed weekly questionnaires quantifying asthenia/fatigue.

70 ties included nausea and vomiting, alopecia, asthenia, fever, and anemia.

71 of 96 patients), diarrhoea (five [5%]), and asthenia (five [5%]).

72 e most common nonhematologic toxicities were asthenia, flu-like symptoms, and fluid retention.

73 lacebo group), rash (four [6%] vs none), and asthenia (four [6%] vs one [2%]).

74 five [12%] of 42 in the placebo group), and asthenia (four [9%] of 44 patients in the selumetinib gr

75 The most common adverse events were asthenia, headache, and fatigue.

76 y or probably related to study drug included asthenia, headache, and nausea.

77 Hereditary equine regional dermal asthenia (HERDA), a degenerative skin disease that affec

78 en patients had dose-limiting but reversible asthenia, hyperbilirubinemia, and azotemia or acidosis;

79 aneous squamous-cell carcinoma in ten (12%), asthenia in four (5%), and basal-cell carcinoma in four

80 e patients), diarrhea (in 59.4%), fatigue or asthenia (in 59.0%), decreased appetite (in 50.2%), decr

81 Adverse events included headaches, asthenia, infections, and hypersensitivity.

82 openia, thrombocytopenia, anemia, fatigue or asthenia, leukopenia, and increased alanine aminotransfe

83 events overall were headache (n = 22 [19%]), asthenia (n = 16 [14%]), and fatigue (n = 11 [10%]).

84 enias (n = 10), nausea/vomiting (n = 9), and asthenia (n = 5).

85 mar-plantar erythrodysesthesia [PPE], n = 3; asthenia, n = 2; cardiac, n = 2; neutropenia, n = 1; sto

86 se related: injection site reactions, cough, asthenia, nausea, anorexia, weight loss, and increased s

87 Nausea, pruritus, insomnia, diarrhea, and asthenia occurred in significantly more patients in grou

88 The most common toxicities were asthenia, occurring in 83% of patients (grade 3 or 4 in

89 sorders (three [13%] at 200 mg twice a day), asthenia (one [7%] at 300 mg twice a day), infections an

90 st common adverse events in both groups were asthenia or fatigue (270 [54%] of 503 patients on eribul

91 3%, respectively), diarrhea (34.6% v 41.0%), asthenia or fatigue (43.5% v 38.1%), and neutropenia (gr

92 150 [40%]), diarrhoea (97 [26%] vs 30 [8%]), asthenia or fatigue (91 [24%] vs 45 [12%]), and peripher

93 ual loss, decreased coordination, widespread asthenia, paraplegia, quadriplegia, and sensory impairme

94 Drug-related adverse events such as asthenia, poor appetite, dizziness, nausea, and vomiting

95 Common adverse events included headache, asthenia, pruritus, and diarrhea.

96 y; most common toxicities included diarrhea, asthenia, rash, nausea, and vomiting.

97 le patients and were characterized by cough, asthenia, sensory neuropathy, anorexia, serum sickness,

98 atients given LY334370 than placebo reported asthenia, somnolence, and dizziness.

99 Many other factors contribute to asthenia, such as anaemia, autonomic failure, and muscul

100 commonly reported adverse events were fever, asthenia, transaminase elevation, nausea, and skin toxic

101 Grade 3 asthenia was dose limiting at the highest dose level tes

102 re common in the temsirolimus group, whereas asthenia was more common in the interferon group.

103 g and 60 mg, respectively; transient grade 3 asthenia was observed on schedule A at 80 mg (one patien

104 Grade III fatigue and asthenia were observed in all three patients treated at